Jeremy D Gale Selected Research

ropsacitinib

1/2022

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeremy D Gale Research Topics

Disease

2	Fibrosis (Cirrhosis) 01/2021 - 09/2018
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2020 - 11/2004
2	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/2011 - 09/2010
2	Hypersensitivity (Allergy) 01/2011 - 09/2010
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022
1	Brain Diseases (Brain Disorder) 01/2021
1	Ascites 01/2021
1	Hemorrhage 01/2021
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021
1	Chronic Hepatitis C 01/2021
1	Obstructive Jaundice (Cholestatic Jaundice) 01/2021
1	End Stage Liver Disease 01/2021
1	Disease Progression 01/2020
1	Crohn Disease (Crohn's Disease) 01/2020
1	Albuminuria 11/2018
1	Type 2 Diabetes Mellitus (MODY) 11/2018
1	Diabetic Nephropathies (Diabetic Nephropathy) 11/2018
1	Cicatrix (Scar) 09/2018
1	Surgical Wound 09/2018
1	Hypertrophic Cicatrix (Hypertrophic Scar) 09/2018
1	Macular Edema 01/2018
1	Constipation 05/2009
1	Colitis 11/2004
1	Inflammation (Inflammations) 11/2004

Drug/Important Bio-Agent (IBA)

3	LigandsIBA 01/2018 - 09/2010
2	Pharmaceutical PreparationsIBA 01/2020 - 11/2004
2	CC ChemokinesIBA 11/2018 - 01/2018
2	PF-04634817IBA 11/2018 - 01/2018
2	Pregabalin (Lyrica)FDA Link 01/2011 - 09/2010
1	ropsacitinibIBA 01/2022
1	TYK2 Kinase (Tyrosine Kinase 2)IBA 01/2022
1	CollagenIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Biological ProductsIBA 01/2020
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2018
1	Chemokine ReceptorsIBA 11/2018
1	Angiotensin Receptor AntagonistsIBA 11/2018
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 11/2018
1	ChemokinesIBA 11/2018
1	Proteins (Proteins, Gene)FDA Link 09/2018
1	Antisense OligonucleotidesIBA 09/2018
1	Connective Tissue Growth FactorIBA 09/2018
1	Ranibizumab (Lucentis)FDA Link 01/2018
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2011
1	Calcium Channels (Calcium Channel)IBA 09/2010
1	ChloridesIBA 05/2009
1	tegaserod (Zelnorm)FDA Link 05/2009
1	Chloride Channels (Chloride Channel)IBA 05/2009
1	Lubiprostone FDA Link 05/2009
1	Dexamethasone (Maxidex)FDA LinkGeneric 11/2004
1	CytokinesIBA 11/2004
1	Interleukin-8 (Interleukin 8)IBA 11/2004

Therapy/Procedure

2	Therapeutics 01/2022 - 11/2018
1	Liver Transplantation 01/2021
1	Intradermal Injections 09/2018